Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer
- 193 Downloads
Introduction and Purpose
The purposes of this study are to evaluate the activity and safety of preoperative intensity-modulated radiotherapy and concurrent capecitabine and oxaliplatin (Xelox), the accuracy of preoperative magnetic resonance (MRI) for predicting pathologic results, and the correlation between carcinoembryonic antigen (CEA) and the existence of a pathologic complete response (pCR).
Patients and Methods
Twenty-seven patients (pt) with T3/T4N0/N+ rectal cancer were included. Capecitabine was administered at 825 t.i.d. mg/m2 the days of the radiotherapy (RT), and oxaliplatin was administered weekly at 50 mg/m2. RT was planned to 50.4 Gy. Surgery was scheduled 6 to 8 weeks after completion of Xelox RT. Before the intervention, a pelvic MRI was performed and a CEA level was determined.
After Xelox RT, 7 pt had pCR (26%), 2 pt progression disease, and 18 pt tumor downstaging. Presurgical MRI did not predict the pathological result in 21 pt. Main side effects were diarrhea grade (G) 3 in four pt, hand and foot G1 five Pt and G2 four pt. Paresthesias G1 ten pt, G2 seven pt, and leukopenia six pt G1. Median RT dose was 49.7 Gy (47.5–50.4 Gy). At a mean follow-up of 22.5 months, four pt presented metastatis. Mean pretreatment CEA was 6.8 ng/mL (2.1–17.0). A difference statistically significant when compared pretreatment CEA with presurgical CEA (p < 0.001) was detected. We found a nadir of <5 ng/mL as significantly associated with pCR (p = 0.036).
Preoperative chemoradiotherapy with oxaliplatin and capecitabine is safe and well tolerated, and offers an interesting ratio of pCR and of tumor downstaging. Presurgical CEA level should be studied as predictors of pCR.
KeywordsRectal cancer Neoadjuvant Preoperative MRI CEA nadir
- 14.Carlomagno C, Farella A, Bucci L, D’Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D’Armiento MR, De Placido S. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol. 2009;20:906–12.PubMedCrossRefGoogle Scholar
- 16.Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (fu)- based choradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante reto( STAR)-01 randomized phase III trial (abstract #4008). J Clin Oncol. 2009;27:804s.Google Scholar
- 19.Nazato DM, Matos LL, Waisberg DR, Souza JR, Martins LC, Waisberg J. Prognostic value of carcinoembryonic antigen distribution in tumor tissue of colorectal carcinoma. J Arq Gastroenterol. 2009;46:26–31.Google Scholar
- 26.Rutten H, Sebag-Montefiore D, Glynne-Jones R et al. Capecitabine, oxaliplatin, radiotherapy and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol. 2006;24 (Suppl): (Abstr 3528).Google Scholar
- 27.Majem M, Navarro M, Losa F et al. Phase II clinical trial of weekly oxaliplatin with concurrent capecitabine plus preoperative radiotherapy in locally advanced respectable rectal cancer. J Clin Oncol. 2008;26 (Suppl): (Abstr 15013).Google Scholar
- 29.Alonso V, Lambea J, Salud A et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal carcinoma: a phase II trial. J Clin Oncol. 2007;25 (Suppl): (Abstr 4044).Google Scholar